Among them, the small inhibitor SR-18292 improved the metabolic outcome of diabetes type 2, a condition frequently associated with MASLD and its sequelae, by blocking the gluconeogenic pathway and, more in particular, displacing the interaction between Pgc1α and Hnf4α.40 Here, PPARGC1A is linked to metabolic dysfunction-associated steatotic liver disease.